{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"# of participants with any grade infusion reaction"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"# of participants with G3/4 infusion reaction"}],"denoms":[{"counts":[{"groupId":"OG000","value":"70"}],"units":"Participants"}],"description":"An infusion reaction in this study is defined as any relevant sign or symptom occurring during or after elotuzumab infusion and considered by the investigator as an infusion reaction. Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Potentially Life-threatening or disabling, Gr 5=Death.","groups":[{"description":"E-Ld refers to the combination of Elotuzumab with Lenalidomide/Dexamethasone.","id":"OG000","title":"E-Ld"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All treated participants","reportingStatus":"POSTED","timeFrame":"Date of first dose up to 60 days post last dose (approximately 4 years)","title":"Number of Participants With Any Grade and Grade 3 or Grade 4 (G3/4) Infusion Reactions Over the Entire Study Period","type":"SECONDARY","unitOfMeasure":"Participants"}